These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22457212)

  • 1. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
    Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
    Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMP4 promotes prostate tumor growth in bone through osteogenesis.
    Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
    Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous hedgehog antagonist delays but does not prevent fracture healing in young mice.
    Liu X; McKenzie JA; Maschhoff CW; Gardner MJ; Silva MJ
    Bone; 2017 Oct; 103():241-251. PubMed ID: 28734986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signaling mediates woven bone formation and vascularization during stress fracture healing.
    Kazmers NH; McKenzie JA; Shen TS; Long F; Silva MJ
    Bone; 2015 Dec; 81():524-532. PubMed ID: 26348666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.
    Hwang RF; Moore TT; Hattersley MM; Scarpitti M; Yang B; Devereaux E; Ramachandran V; Arumugam T; Ji B; Logsdon CD; Brown JL; Godin R
    Mol Cancer Res; 2012 Sep; 10(9):1147-57. PubMed ID: 22859707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
    Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
    Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers.
    Efstathiou E; Karlou M; Wen S; Hoang A; Pettaway CA; Pisters LL; Maity S; Troncoso P; Logothetis CJ
    Prostate; 2013 Jan; 73(2):153-61. PubMed ID: 22753310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
    LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
    Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
    Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
    Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β
    Zhang M; Wang Q; Sun X; Yin Q; Chen J; Xu L; Xu C
    Prostate; 2020 Nov; 80(15):1328-1340. PubMed ID: 32894788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
    Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
    Lee YC; Lin SC; Yu G; Cheng CJ; Liu B; Liu HC; Hawke DH; Parikh NU; Varkaris A; Corn P; Logothetis C; Satcher RL; Yu-Lee LY; Gallick GE; Lin SH
    Cancer Res; 2015 Nov; 75(22):4949-59. PubMed ID: 26530902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.
    Singh BN; Fu J; Srivastava RK; Shankar S
    PLoS One; 2011; 6(11):e27306. PubMed ID: 22087285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.